8-K: MoonLake Immunotherapeutics Secures $500 Million Non-Dilutive Financing from Hercules Capital

MoonLake Immunotherapeutics has secured a non-dilutive term loan facility of up to $500 million from Hercules Capital to advance its clinical programs and prepare for the potential launch of sonelokimab.

Summary

• MoonLake Immunotherapeutics has entered into a loan and security agreement with Hercules Capital for a non-dilutive term loan facility of up to $500 million.
• The facility includes a fully committed first tranche of $75 million funded on March 31, 2025.
• Additional tranches are contingent upon achieving milestones related to Phase 3 studies of sonelokimab (SLK) in hidradenitis suppurativa (HS) and psoriatic arthritis (PsA), as well as FDA acceptance of a biologics license application for SLK.
• The credit facility matures on April 1, 2030, and bears interest at an annual rate equal to the greater of (i) prime rate as reported in The Wall Street Journal plus 1.45% and (ii) 8.45%, subject to a 0.25% reduction upon achievement of the U.S. Food and Drug Administrations acceptance of a biologics license application for SLK.
• The proceeds will be used for working capital and general corporate purposes.
• MoonLake plans to hold a Capital Markets Update on April 29, 2025, to discuss the Hercules partnership and provide clinical updates.
• The company is progressing eight Phase 2 and Phase 3 clinical trials and expects to read out pivotal Phase 3 data for HS in mid-2025.
• An interim readout from the Phase 2 LEDA trial of sonelokimab in palmoplantar pustulosis (PPP) is also anticipated.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant non-dilutive financing secured, which strengthens the company's financial position and supports its clinical development programs. Management expresses confidence in the advancement of sonelokimab and the company's ability to execute its strategy.

Positives

• The $500 million non-dilutive financing strengthens MoonLake's balance sheet without diluting shareholder equity.
• The financing provides capital to advance sonelokimab in multiple indications and build commercial readiness.
• The deal terms include a sizable commitment and a competitive cost of capital.
• The company has a robust cash position, further bolstered by this financing.
• The Phase 2 LEDA trial in PPP recruited faster than anticipated, allowing for an earlier data readout.
• The company expects to share details on patient baseline characteristics for the VELA program and narrowed guidance with respect to the timing of the primary endpoint read-out.

Negatives

• Access to the additional tranches of the loan is contingent upon achieving specific clinical and regulatory milestones, introducing uncertainty.
• The credit facility bears interest at an annual rate equal to the greater of (i) prime rate as reported in The Wall Street Journal plus 1.45% and (ii) 8.45%, subject to a 0.25% reduction upon achievement of the U.S. Food and Drug Administrations acceptance of a biologics license application for SLK.
• The company is subject to customary covenants, including, without limitation, liquidity covenant and negative covenants that, subject to certain exceptions, restrict indebtedness, liens, investments (including acquisitions), fundamental changes, asset sales and licensing and royalty transactions, dividends, modifications to material agreements, payment of subordinated indebtedness, and other matters customarily restricted in such agreements.

Risks

• Failure to achieve the Tranche 2, Tranche 3 and Tranche 4 Milestones would limit access to the full $500 million Credit Facility.
• Clinical trial results may not be positive, which could impact the availability of future tranches.
• Regulatory approval for SLK is not guaranteed.
• The company is subject to customary covenants, including, without limitation, liquidity covenant and negative covenants that, subject to certain exceptions, restrict indebtedness, liens, investments (including acquisitions), fundamental changes, asset sales and licensing and royalty transactions, dividends, modifications to material agreements, payment of subordinated indebtedness, and other matters customarily restricted in such agreements.
• The Loan and Security Agreement also contains certain events of default after which loans under the Credit Facility may be due and payable immediately, including payment defaults, material inaccuracy of representations and warranties, covenant defaults, bankruptcy and insolvency proceedings, cross-defaults to certain other agreements, judgments against the Company and its subsidiaries, cessation of business and change of control.

Future Outlook

MoonLake expects to use the financing to advance sonelokimab in multiple indications, build commercial readiness, and potentially launch the product in 2027.

Management Comments

• Matthias Bodenstedt, Chief Financial Officer at MoonLake Immunotherapeutics, said: 'We are extremely excited to partner with Hercules Capital that recognizes the value and potential of sonelokimab. We were able to secure deal terms, including a very sizable commitment and a highly competitive cost of capital. This financing facility further bolsters our already robust cash position without diluting our shareholders stakes and effectively removes any perceived financing overhang as we approach our pivotal data readout for the HS VELA program this summer.'
• Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: 'The new $500 million facility further strengthens our financial position. With this facility and existing cash balance, we are in control of our financing strategy, and we can drive the advancement of sonelokimab in multiple indications, while building our commercial readiness activities including in the United States. I am confident that narrowed guidance on the VELA primary endpoint readout and the presentation of baseline characteristics will continue to demonstrate our ability to execute and further validate the expectations on sonelokimab. I am very glad that the PPP Phase 2 LEDA trial recruited much faster than anticipated and that we will be able to share data with the market sooner than expected. This will further contribute to building the position of sonelokimab as a high-potential, multi-indication asset that can truly change the lives of patients.'

Industry Context

This financing reflects a trend of biotechnology companies seeking non-dilutive funding options to advance their clinical programs. Hercules Capital is a prominent lender in the life sciences sector, providing customized debt financing to companies like MoonLake.

Comparison to Industry Standards

• Securing a $500 million non-dilutive facility is a significant achievement for a development-stage therapeutics company, setting a new standard for the quantum of a nondilutive facility.
• Comparable companies in the biotechnology space often rely on a mix of equity and debt financing to fund their research and development activities.
• The terms of the loan, including the interest rate and milestones, are likely benchmarked against similar deals in the industry.

Stakeholder Impact

• Shareholders benefit from the non-dilutive nature of the financing.
• Employees are supported by the increased financial stability of the company.
• Patients may benefit from the advancement of sonelokimab as a potential treatment for inflammatory diseases.
• The company's financial strength may improve relationships with suppliers and creditors.

Next Steps

• Advance sonelokimab through Phase 2 and Phase 3 clinical trials.
• Prepare for the potential launch of sonelokimab in 2027.
• Present clinical updates at the Capital Markets Update on April 29, 2025.
• Achieve milestones to unlock additional tranches of the loan facility.

Key Dates

Keywords

sonelokimab, financing, Hercules Capital, clinical trials, hidradenitis suppurativa, psoriatic arthritis, loan, biotechnology, immunotherapeutics, Nanobody